SLC2A1 and colorectal cancer: Colorectal cancer cells with KRAS or BRAF mutations show enhanced glucose metabolism such as glucose uptake and glycolysis, and require expression of glucose transporter-1 (GLUT-1), a membrane glucose transporter4,5.